Castle Biosciences Inc CSTL
We take great care to ensure that the data presented and summarized in this overview for CASTLE BIOSCIENCES INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CSTL
View all-
Black Rock Inc. New York, NY2.6MShares$63.3 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT2.55MShares$62.2 Million0.3% of portfolio
-
Granahan Investment Management, LLC Waltham, MA1.63MShares$39.7 Million1.3% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.53MShares$37.3 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.49MShares$36.4 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.22MShares$29.7 Million0.42% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.04MShares$25.4 Million1.8% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY928KShares$22.6 Million0.42% of portfolio
-
Dimensional Fund Advisors LP Austin, TX749KShares$18.3 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT725KShares$17.7 Million1.31% of portfolio
Latest Institutional Activity in CSTL
Top Purchases
Top Sells
About CSTL
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Insider Transactions at CSTL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 03
2024
|
Derek J Maetzold Pres. & Chief Exec. Officer |
SELL
Open market or private sale
|
Indirect |
3,968
-1.7%
|
$91,264
$23.68 P/Share
|
|
Jun 03
2024
|
Derek J Maetzold Pres. & Chief Exec. Officer |
SELL
Open market or private sale
|
Direct |
2,368
-1.97%
|
$54,464
$23.68 P/Share
|
|
May 25
2024
|
Kim Caple Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,636
+39.3%
|
-
|
|
May 25
2024
|
Daniel Bradbury Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,636
+39.39%
|
-
|
|
May 25
2024
|
Miles Harrison Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,636
+39.39%
|
-
|
|
May 25
2024
|
Ellen Goldberg Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,636
+32.25%
|
-
|
|
May 25
2024
|
G Bradley Cole Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,636
+39.39%
|
-
|
|
May 25
2024
|
Tiffany Olson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,636
+34.49%
|
-
|
|
May 23
2024
|
Mara G. Aspinall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,636
+16.36%
|
-
|
|
May 14
2024
|
Derek J Maetzold Pres. & Chief Exec. Officer |
SELL
Open market or private sale
|
Indirect |
3,968
-1.65%
|
$95,232
$24.56 P/Share
|
|
May 14
2024
|
Derek J Maetzold Pres. & Chief Exec. Officer |
SELL
Open market or private sale
|
Direct |
2,368
-1.9%
|
$56,832
$24.56 P/Share
|
|
May 10
2024
|
Tiffany Olson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
487
+5.9%
|
-
|
|
May 06
2024
|
Daniel Bradbury Director |
SELL
Open market or private sale
|
Indirect |
23,323
-35.39%
|
$559,752
$24.64 P/Share
|
|
May 06
2024
|
Derek J Maetzold Pres. & Chief Exec. Officer |
SELL
Open market or private sale
|
Indirect |
3,968
-3.16%
|
$95,232
$24.72 P/Share
|
|
May 06
2024
|
Derek J Maetzold Pres. & Chief Exec. Officer |
SELL
Open market or private sale
|
Direct |
2,368
-3.64%
|
$56,832
$24.72 P/Share
|
|
Apr 23
2024
|
Derek J Maetzold Pres. & Chief Exec. Officer |
SELL
Open market or private sale
|
Indirect |
705
-0.56%
|
$14,100
$20.11 P/Share
|
|
Apr 23
2024
|
Derek J Maetzold Pres. & Chief Exec. Officer |
SELL
Open market or private sale
|
Direct |
421
-0.64%
|
$8,420
$20.11 P/Share
|
|
Apr 12
2024
|
Derek J Maetzold Pres. & Chief Exec. Officer |
SELL
Open market or private sale
|
Indirect |
3,263
-2.51%
|
$65,260
$20.35 P/Share
|
|
Apr 12
2024
|
Derek J Maetzold Pres. & Chief Exec. Officer |
SELL
Open market or private sale
|
Direct |
1,947
-2.89%
|
$38,940
$20.35 P/Share
|
|
Apr 08
2024
|
Daniel Bradbury Director |
SELL
Open market or private sale
|
Indirect |
2,400
-3.5%
|
$48,000
$20.45 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 217K shares |
|---|
| Open market or private sale | 463K shares |
|---|---|
| Payment of exercise price or tax liability | 36.7K shares |